A fundamental obstacle in gene therapy for cancer treat-1954 , by a factor of 22. To demonstrate the specificity of ment is the specific delivery of an anticancer gene product this approach for tumor targeting, we intravenously injected to a solid tumor. Although several strategies exist to control the inactive spore form of C. beijerinckii, which upon trangene expression once a vector is directly introduced into a sition to a reproductive state will express the E. coli nitroretumor, as yet no systemic delivery system exists that ductase gene. Nitroreductase activity was detectable in 10 specifically targets solid tumors. Nonpathogenic, obligate of 10 tumors during the first 5 days after intravenous injecanaerobic bacteria of the genus Clostridium have been tion of inactive clostridial spores, indicating a rapid tranused experimentally as anticancer agents because of their sition from spore to reproductive state. Tumors harboring selective growth in the hypoxic regions of solid tumors after clostridial spores which did not possess the E. coli nitroredsystemic application. In this report we further describe a uctase gene were devoid of nitroreductase activity. Most novel approach to cancer gene therapy in which genetically importantly, E. coli nitroreductase protein was not found in engineered clostridia are used as tumor-specific vectors for a large survey of normal mouse tissues following intrathe delivery of antitumor genes. We have introduced into venous injection of nitroreductase containing clostridia, a strain of C. beijerinckii the gene for an E. coli nitroreducIntroduction antitumor agent. Cancer patients, particularly those with It has been known for several decades that certain species glioblastoma multiforme, were injected intravenously of anaerobic bacteria, of the genus Clostridium, can selecwith up to 10 10 C. oncolyticum spores. 8, 9 As with the anitively germinate and grow in the hypoxic regions of solid mal tumors, most of the human malignancies experitumors after intravenous injection. These hypoxic regions enced partial lysis with no evidence of clostridial germiare characteristic of solid tumors in rodents 1 and occur nation or tissue destruction in the surrounding normal with high frequency in many human tumors. 2 tissue. Furthermore, with the exception of mild to moderThe tumor selective germination of clostridia was draate fever, the patients suffered no ill effects from the matically demonstrated by Malmgren and Flanigen 3 with injection of these organisms in large numbers. Unfortu-C. tetani, the causative agent of tetanus. Mice, when nately, C. oncolyticum by itself did not produce significant injected intravenously with spores of C. tetani, remained antitumor activity, so the trials were discontinued. healthy unless they had tumors, in which case death by
We hypothesized that clostridia could be genetically tetanus resulted within 48 h. This occurred because the manipulated, thereby exploiting tumor hypoxia for a new bacteria were able to germinate in the tumors, thereby form of gene therapy ( Figure 1 ). We have previously releasing toxins systemically. Mö se and colleagues 4 later reported on the genetic manipulation of C. beijerinckii to isolated a nonpathogenic strain of C. sporogenes called produce the E. coli enzymes cytosine deaminase 10 and M55 (this strain was later renamed C. oncolyticum). These nitroreductase, 11 enzymes known to activate nontoxic and subsequent authors were interested in these nonprodrugs to toxic anticancer drugs. This article describes pathogenic bacteria as anticancer agents because their the selective production of E. coli nitroreductase in germination in tumors resulted in a partial tumor lysis. 5, 6 murine tumors in situ following the intravenous injection More importantly, it was demonstrated that the clostridia of genetically modified C. beijerinckii spores. germinated solely in the tumor after intravenous injection E. coli nitroreductase activates the prodrug CB 1954 (5-of the inactive spore form. Anlezark and colleagues 13 from E. coli B. CB 1954, a monGram staining of histological sections indicated that clostridia did not germinate in normal tissues, including ofunctional alkylating agent originally synthesized over 25 years ago, 14 has potent activity against Walker 256 rat heart, kidney, liver, lung and spleen ( Figure 2d ). carcinoma cells due to efficient drug reduction to the toxic bifunctional alkylating agent by rat (but not human)
Tumor cell killing by clostridia-activated CB 1954 in vitro DT-diaphorase. 15 E. coli B nitroreductase is approximately Survival of EMT6 tumor cells in culture exposed to the 30-fold more efficient than rat DT-diaphorase at producprodrug CB 1954 was examined by exposing tumor cells ing the active form of CB 1954. 16 to media in which clostridia, with or without the nitroreAs described above, most of the early clostridia tumor ductase gene, had been grown. Supernatant from clostristudies were performed with C. oncolyticum M55, a strain dia containing the nitroreductase plasmid (pNTR500F) of C. sporogenes. However, selective germination in expressed 100-200 mU nitroreductase activity per ml, as tumors after intravenous injection has also been reported assayed by following the reduction of dichlorophenolwith other species, including C. acetobutylicum, 17 which indophenol with a spectrophotometer. There was a 22-for many decades has been used as a commercial profold increase in cell killing by CB 1954 when the clostriducer of acetone and butanol. Since plasmid vectors and dia-produced nitroreductase was present ( Figure 3a ). transformation procedures are available for C. acetobutylSimilar cell survival results were obtained with SCCVII icum and not for C. sporogenes, we used a strain of C. acetomouse tumor cells (data not shown). Reduction of CB butylicum (recently reclassified as C. beijerinckii) in our 1954 by the nitroreductase-producing clostridia but not studies. In this article, we present evidence for the tumorby control clostridia was confirmed by measuring loss of specific expression of E. coli B nitroreductase, using the parent drug with high pressure liquid chromato-C. beijerinckii as the gene delivery vector.
graphy in samples taken from these survival experiments ( Figure 3b ).
Results

Immunoblot detection of nitroreductase in tumors
Mice bearing EMT6 tumors were injected intravenously Selective growth of unmodified clostridia in tumors To demonstrate that systemically applied clostridia grow with spores containing the nitroreductase plasmid, or with spores containing the empty plasmid (pMTL500F). selectively in tumors, EMT6 tumor-bearing mice were injected intravenously with 10 8 wild-type clostridial Nitroreductase protein was detected by immunoblot analysis in nine of 10 tumors removed 1-5 days after spores, killed 24 h later, and examined for the presence of Gram-positive clostridial rods in both tumors and normal intravenous injection of clostridia containing the nitroreductase gene (Figure 4a ). The amount of nitroreductase tissues. Tumors exhibited a heavy infestation of Grampositive staining rods in and surrounding the region of correlated with the numbers of viable clostridia found in these tumors, which ranged from 10 5 -10 6 per gram of central necrosis, a region presumed to be at low oxygen tension (Figure 2b, c) . 18 A light scattering of Gramtumor, and on average 78% of the bacteria contained the plasmid (±27, 1 s.d.m.). These bacteria were almost all positive rods was infrequently found elsewhere in the tumors. Control tumors from mice injected with (Ͻ96%) in the non-spore form, indicating germination of the spores in the tumors as early as 24 h after spore injecphosphate-buffered saline alone stained negative for the presence of Gram-positive rods (Figure 2a ). In addition, tion. Plasmid control tumors, which had similar numbers of viable bacteria at the time of harvest, had no detectable heart, upper intestine (jejunum region), lower intestine with resident feces, kidney, liver, lung, skeletal muscle nitroreductase protein by immunoblot assay (Figure 4a ).
Significant nitroreductase activity was detected in pro-(gastrocnemius) and spleen. Of these tissues, immunoblots for all except hearts are shown in Figure 4b . No tein preparations of all 10 tumors obtained from mice injected with clostridia containing the nitroreductase detectable nitroreductase protein was present in any of these tissues. A protein with weak cross-reactivity that plasmid (Figure 4a ). Nitroreductase activity in plasmid control tumors was at least several orders of magnitude possesses a similar molecular weight to nitroreductase was detected in the small intestine and skeletal muscle. lower and could not be detected (Figure 4a ). The enzyme activity in these tumors in vivo was roughly equivalent However, these weak cross-reactivities were also found in untreated mice (data not shown). Protein extracts from on an activity per volume basis to that seen in the medium of stationary phase clostridia growing in an heart tissue exhibited antibody cross-reactivity similar in intensity and molecular weight to that found in tumors anaerobic chamber (ie the activity in a 500 mm 3 tumor was approximately the same as the activity in 0.5 ml of (Figure 4c ). Since cross-reactivity was also present in immunoblots from protein preparations of hearts from supernatant from a nitroreductase-producing clostridial culture).
mice that had been injected with plasmid control clostridia, as well as from untreated mice (Figure 4c ), we conclude that this protein in mouse heart is naturally occurImmunoblot detection of nitroreductase in normal tissues ring and is not E. coli nitroreductase. Thus, production of nitroreductase by clostridia after intravenous injection Normal tissues from the five mice with the strongest nitroreductase protein levels in their tumors were examinto tumor-bearing mice was found to be specific to the tumors. ined by immunoblot assay. Tissues examined were brain, organisms in humans was initially demonstrated by Mö se et al (cited in Ref. 8 ) when the authors injected themselves with C. oncolyticum spores, and experienced a mild fever as the only side-effect. The lack of pathogenicity was also substantiated in clinical trials with C. oncolyticum 8, 9 and also in more recent trials with a strain of C. beijerinckii. 19 As a further safeguard for this gene delivery system, we chose to express in clostridia a drug-activating enzyme rather than a protein that could kill tumor cells directly, and which might produce host toxicity if it found its way into the systemic circulation. A further advantage of expressing drug-activating enzymes is its amplification potential, since one enzyme molecule can activate many molecules of prodrug. The nitroreductase/CB 1954 enzyme prodrug system is one of several enzyme prodrug schemes that are currently being investigated in other laboratories (reviewed in Ref. 20) .
In summary, we have demonstrated the principle that a nonpathogenic species of clostridia can be engineered to express a foreign gene product selectively in a solid tumor after intravenous injection of the inactive spore form. When these genetically engineered clostridia are introduced systemically into tumor-bearing mice, the product of the introduced enzyme gene is found only in the tumors, presumably due to the hypoxic environment required for growth of these bacteria. We believe that this new delivery system holds promise for gene therapy of solid tumors, because of its lack of toxicity and highly selective growth in tumors.
Figure 3 EMT6 tumor cell survival and drug metabolism in the presence of the prodrug CB 1954 and clostridia-produced nitroreductase. (a) EMT6 survival after a 2 h exposure to CB 1954 in combination with clostridial supernatant from wild-type or nitroreductase (NTR) gene containing clos-
Materials and methods
tridia. Each data point represents one independent survival measurement. Two experiments are combined. (b) CB 1954 metabolism after a 2 h
Tumor cell survival assays Research, Sutton, UK. EMT6 tumor cells were seeded into 60 mm plastic tissue culture dishes, allowed to grow for 2 days, and treated when about 30-50% confluent by Discussion replacing the media with supernatant from C. beijerinckii cultures. Following overnight growth, C. beijerinckii conThe central problem for gene therapy of cancer is the lack of specificity of current delivery systems. To date no taining the plasmid with or without the nitroreductase gene were diluted 1:10 in bacterial media and allowed to technique exists for the specific delivery of novel genes to tumors when the delivery system is systemically grow to stationary phase, as determined by optical density at 600 nm. This is the stage of bacterial growth where injected. We further describe a novel approach to this problem, the production of antitumor agents by genetiwe found the largest quantity of active nitroreductase in the bacterial media (data not shown). The clostridial culcally modified obligate anaerobic bacteria. We have demonstrated a highly tumor-specific localization of the protures were then centrifuged and the pH of the supernatant, which was typically about 5.0, was adjusted to 7.4 duct of clostridial gene expression in tumor-bearing mice after systemic application. The lack of clostridial gene with NaOH. The tumor cells were treated for 2 h at 37°C with clostridial supernatant in combination with CB 1954 products in normal tissues indicates not only that the oxygen tension in these tissues is sufficiently high to preand 500 m NADH. After treatment, the bacterial supernatant was removed, the tumor cells were washed three vent clostridial germination, but also that the gene products do not circulate from the tumor to other tissues via times with PBS, trypsinized, counted with a Coulter counter (Hialeah, FL, USA) and plated at various the bloodstream or other routes. The only requirement for success of this gene therapy technique in the clinic dilutions in fresh medium to assay for clonogenic survival. After an 8 day incubation at 37°C, tumor cells were should be the presence of hypoxia in the tumors being treated. Disseminated as well as primary disease should stained with crystal violet, and colonies containing at least 50 cells were counted. Clonogenic cell survival was be amenable to treatment as long as regions of hypoxia are present -in fact growth of clostridia in metastatic calculated relative to that of untreated controls. Samples of supernatant were analyzed at the end of treatment for lesions of human cancer patients after intravenous injection of clostridial spores has already been demonstrated. 8 metabolism of CB 1954 by high pressure liquid chromatography (HPLC) by a procedure similar to that of SunThis gene delivery system is not only tumor specific, it is also nontoxic. The lack of pathogenicity of these ters et al, 21 using a Water's Maxima system (Milford, MA, USA). Samples were diluted in mobile phase buffer (25% Introduction and selection for the nitroreductase gene E. coli B nitroreductase was isolated by polymerase chain methanol, 0.1 m amonium acetate, pH 7.0), and separated on a C 18 column at a flow rate of 5 ml/min. The reaction and cloned into the NdeI and PstI restriction sites of the multiple cloning region of the pMTL500F shuttle absorbance of the effluent was monitored at 325 nm.
vector, resulting in constitutive expression of the nitroreductase gene in clostridia. 11 This plasmid is called Spore induction and systemic delivery to tumor-bearing mice pNTR500F. 2 × YTG medium was supplemented with 20 g/ml erythromycin or clarythromycin for selection of C. beijerinckii NCIMB 8052 was grown in an anaerobic chamber (Sheldon Manufacturing Bactron II, Cornelius, bacteria containing the introduced plasmids, which have an erythromycin resistance gene. Clostridial spores, con-OR, USA) at 37°C in 2 × YTG media (16 g tryptone, 10 g peptone, 5 g NaCl and 5 g glucose per liter). Sporulation taining either the control or nitroreductase plasmid, were injected intravenously into tumor-bearing mice as was induced by either the method of Kashket and Cao, 22 or the bacteria were left to sporulate for 2-3 weeks on described above. Mice were also given subcutaneous injections twice daily of 50 mg/kg azithromycin (Pfizer, 1.5% agar plates of 2 × YTG media. Following spore harvest, contaminating bacterial rods were removed accordGroton, CT, USA) to maintain selective pressure for plasmid retention. 25 One to five days after intravenous injecing to the protocol of Kihm et al, 23 after which the spore suspensions were washed and resuspended in phostion of spores, mice were killed by cervical dislocation and their tumors and normal tissues were removed. phate-buffered saline for mouse injection. Balb/c female mice, 2.5-3 months old, were injected intradermally in Tumor samples were plated under anaerobic conditions before and after a 70°C 10 min heat shock to determine the sacral region of the back with 2 × 10 5 EMT6 mouse mammary carcinoma cells in 50 l of Waymouth's the number of viable bacteria and spores in each specimen, respectively. medium. The mice were bred and raised under specific pathogen-free conditions in the Stanford Medical School Research Animal Facility, and were provided sterilized
Analysis of E. coli B nitroreductase protein and activity in tumor and normal tissue water and rodent chow ad libitum. Bacterial spores (10 8 ) were injected intravenously when the tumors were Fifty micrograms of protein extracts and 5 ng of purified nitroreductase protein 26 were electrophoresed on a 12.5% approximately 200 mm 3 . For histological analysis, the animals were killed 24 h after spore injection, tumors and SDS-PAGE polyacrylamide gel, transferred to nitrocellulose (Hybond ECL; Amersham, Arlington Heights, IL, normal tissues were excised, sectioned in paraffin, and stained with a modified Gram stain. 24 USA), and stained with Coomassie brilliant blue to
